Paper · 2008 · Open access
Measuring the value of treatment to patients: patient-reported outcomes in drug development.
Europe PMC (PubMed Central), 1(1), 34–40 · Published 1 February 2008
In brief
“Measuring the value of treatment to patients: patient-reported outcomes in drug development.” is a 2008 paper by Richard J. Willke, published in Europe PMC (PubMed Central). OpenAlex counts 24 citations as of 22 November 2026. It is open access: the full text is free to read at Europe PMC (PubMed Central).
- Citations
- 24
- Most cited in
- 2018 (4)
- Field-weighted impact
- 0.56
- References
- 15
- Authors
- 1
Abstract
Patient-reported outcomes (PROs) can be important measures of the impact and value of new drug treatments to patients. Recently, both multisector stakeholder groups and the U.S. Food and Drug Administration have carefully considered and issued guidance on best practices for the use of PROs in measuring treatment impact. When best practices are followed and PRO data are appropriately included in drug development strategy and clinical trials, these data can be part of the evidence submitted for drug approval and included in drug labeling. One study showed that PRO data were included in 30% of a sample of new drug labels and were more concentrated in certain therapeutic areas, such as anti-inflammatory agents, vaccines, gastrointestinal agents, and respiratory and urologic agents. PRO data included in labeling, or generated in a similar scientific manner, may often then be used in other communication vehicles, such as formulary submission dossiers, journal or direct-to-consumer advertisements, publications, or continuing medical education. Meaningful and reliable PRO results regarding the effects of new treatments on how patients feel and function provide useful information to those who must make decisions about the availability and utilization of such treatments.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Willke, R. J. (2008). Measuring the value of treatment to patients: patient-reported outcomes in drug development. Europe PMC (PubMed Central), 1(1), 34–40. https://www.ncbi.nlm.nih.gov/pmc/articles/4114029
MLA 9
Willke, Richard J. “Measuring the value of treatment to patients: patient-reported outcomes in drug development.” Europe PMC (PubMed Central), vol. 1, no. 1, 2008, pp. 34–40. https://www.ncbi.nlm.nih.gov/pmc/articles/4114029.
Chicago
Willke, Richard J. 2008. “Measuring the value of treatment to patients: patient-reported outcomes in drug development.” Europe PMC (PubMed Central) 1 (1): 34–40. https://www.ncbi.nlm.nih.gov/pmc/articles/4114029.
Harvard
Willke, R. J. (2008) ‘Measuring the value of treatment to patients: patient-reported outcomes in drug development.’, Europe PMC (PubMed Central), 1(1), pp. 34–40. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/4114029.
IEEE
R. J. Willke, “Measuring the value of treatment to patients: patient-reported outcomes in drug development.,” Europe PMC (PubMed Central), vol. 1, no. 1, pp. 34–40, 2008.
BibTeX
@article{willke2008measuring,
title = {{Measuring the value of treatment to patients: patient-reported outcomes in drug development.}},
author = {Willke, Richard J.},
journal = {Europe PMC (PubMed Central)},
year = {2008},
volume = {1},
number = {1},
pages = {34--40},
url = {https://www.ncbi.nlm.nih.gov/pmc/articles/4114029}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2015 | 2 | |
| 2016 | 1 | |
| 2017 | 3 | |
| 2018 | 4 | |
| 2019 | 1 | |
| 2021 | 2 | |
| 2022 | 1 | |
| 2024 | 4 | |
| 2025 | 2 | |
| 2026 | 1 |
Its field-weighted citation impact is 0.56: it has been cited 0.56 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcomes
- drug development
- drug approval
- drug labeling
- FDA guidance
- clinical trials
- treatment effects
- treatment value
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Willke, R. J. (2008). Measuring the value of treatment to patients: patient-reported outcomes in drug development. Europe PMC (PubMed Central), 1(1), 34–40. https://www.ncbi.nlm.nih.gov/pmc/articles/4114029
How many times has this paper been cited?
24 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.
Who wrote this paper?
Richard J. Willke.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.